Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Non-Current Liabilities: 2013-2025

Historic Total Non-Current Liabilities for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $411.2 million.

  • Coherus Oncology's Total Non-Current Liabilities fell 27.07% to $411.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $411.2 million, marking a year-over-year decrease of 27.07%. This contributed to the annual value of $551.2 million for FY2024, which is 31.99% down from last year.
  • Per Coherus Oncology's latest filing, its Total Non-Current Liabilities stood at $411.2 million for Q3 2025, which was up 35.75% from $302.9 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Total Non-Current Liabilities registered a high of $842.7 million during Q1 2024, and its lowest value of $302.9 million during Q2 2025.
  • For the 3-year period, Coherus Oncology's Total Non-Current Liabilities averaged around $608.5 million, with its median value being $598.8 million (2023).
  • In the last 5 years, Coherus Oncology's Total Non-Current Liabilities spiked by 82.71% in 2021 and then slumped by 58.58% in 2025.
  • Quarterly analysis of 5 years shows Coherus Oncology's Total Non-Current Liabilities stood at $580.9 million in 2021, then rose by 5.84% to $614.8 million in 2022, then spiked by 31.83% to $810.5 million in 2023, then tumbled by 31.99% to $551.2 million in 2024, then fell by 27.07% to $411.2 million in 2025.
  • Its Total Non-Current Liabilities was $411.2 million in Q3 2025, compared to $302.9 million in Q2 2025 and $523.2 million in Q1 2025.